Johnson & Johnson and a subsidiary have to pay for the way it marketed antipsychotic drug Risperdal, neglecting to mention its side effects while claiming it was safer and worked better than the competition. In Arkansas, one of 11 states in which J&J has faced legal battles over the drug, a judge ordered the company to pay $1.2 billion to make up for its alleged sins. CNNMoney reports the companies' allegedly deceptive practices caused government-subsidized healthcare services to pay for the drug, which is believed to put patients at risk of diabetes and neurological problems.
A Louisiana state court jury has ordered Johnson & Johnson to pay $257.7 million for making misleading claims about the safety and superiority of its Risperdal antipsychotic and, consequently, defrauding the state’s Medicaid system,... Read Post
J&J Ordered to Pay $327 Million Over Deceptive Risperdal Marketing Claims - Bloomberg: "A Johnson & Johnson (JNJ) unit was ordered by a South Carolina judge to pay more than $327 million in penalties for deceptively marketing the an... Read Post